GlobeNewswire Inc.··NodtheraNodThera to Present NLRP3 Drug Program at Major April Investor Conferences
NodThera, a clinical-stage NLRP3 inhibitor biotech, will present at major April 2026 investor conferences including Piper Sandler and Needham.
SNYoral therapyclinical-stage biotech